Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2017 1
2018 2
2019 2
2020 3
2021 4
2022 3
2023 2
2024 2
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Second-Line Antiretroviral Therapy for Children Living with HIV in Africa.
Musiime V, Bwakura-Dangarembizi M, Szubert AJ, Mumbiro V, Mujuru HA, Kityo CM, Lugemwa A, Doerholt K, Chabala C, Makumbi S, Mulenga V, McIlleron H, Burger D, Natukunda E, Shakeshaft C, Linda KJ, Nathoo K, Monkiewicz L, Yawe I, Kapasa M, Nyathi M, Lungu J, Nduna B, Ndebele W, South A, Mwamabazi M, Musoro G, Griffiths A, Zyambo K, Nazzinda R, Zimba K, Zhang Y, Walker S, Turkova A, Walker AS, Bamford A, Gibb DM; CHAPAS-4 Trial Team. Musiime V, et al. N Engl J Med. 2025 May 15;392(19):1917-1932. doi: 10.1056/NEJMoa2404597. N Engl J Med. 2025. PMID: 40367375 Free PMC article. Clinical Trial.
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol.
Gillessen S, Murphy L, James ND, Sachdeva A, El-Taji O, Abdel-Aty H, Adler AI, Amos C, Attard G, Varughese M, Gale J, Brown S, Srihari N, Birtle AJ, Brown M, Chan K, Chowdhury S, Cross W, Dearnaley DP, Din O, Dutey-Magni P, Gilbert DC, Gilson C, Gray S, Grist E, Hofmann U, Hudson AM, Jain Y, Jeyasangar G, Jones R, Kayani M, Langley RE, Malik Z, Mason MD, Matheson D, McAlpine C, Macnair A, Millman R, Murphy C, Padden-Modi M, Parikh O, Parker C, Rush H, Russell M, Srinivasan R, Sundar S, Tanguay JS, Turco F, Williams P, Sydes MR, Parmar MKB, Brown LC, Clarke NW; STAMPEDE investigators. Gillessen S, et al. Lancet Oncol. 2025 Aug;26(8):1018-1030. doi: 10.1016/S1470-2045(25)00231-1. Epub 2025 Jul 7. Lancet Oncol. 2025. PMID: 40639383 Free PMC article. Clinical Trial.
High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.
Jindani A, Harrison TS, Nunn AJ, Phillips PP, Churchyard GJ, Charalambous S, Hatherill M, Geldenhuys H, McIlleron HM, Zvada SP, Mungofa S, Shah NA, Zizhou S, Magweta L, Shepherd J, Nyirenda S, van Dijk JH, Clouting HE, Coleman D, Bateson AL, McHugh TD, Butcher PD, Mitchison DA; RIFAQUIN Trial Team. Jindani A, et al. N Engl J Med. 2014 Oct 23;371(17):1599-608. doi: 10.1056/NEJMoa1314210. N Engl J Med. 2014. PMID: 25337749 Free PMC article. Clinical Trial.
Viral Suppression, Viral Failure, and Safety Outcomes in Children and Adolescents With HIV on Dolutegravir in Europe and Thailand.
Scott K, O'Rourke J, Jackson C, Ene L, Galli L, Goetghebuer T, Henegar C, Königs C, Marczyńska M, Naver L, Noguera-Julian A, Paioni P, Ramos JT, Smith B, Songtaweesin WN, Spoulou V, Tantawarak N, Turkova A, Vannappagari V, Volokha A, Bamford A, Castro H, Chappell E, Dalla Valle G, Foster C, Guillén Martín S, Prieto Tato LM, Puthanakit T, Sherstiuk H, Shkurka I, Soeria-Atmadja S, Judd A, Crichton S, Collins IJ; European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC) study group. Scott K, et al. Clin Infect Dis. 2025 Nov 6;81(4):e115-e127. doi: 10.1093/cid/ciaf191. Clin Infect Dis. 2025. PMID: 40215206 Free PMC article.
BREATHER Plus clinical trial design: A randomised non-inferiority trial evaluating the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily ART in virologically suppressed adolescents living with HIV aged 12 to <20 years in sub-Saharan Africa.
Katongole F, Arumugam T, Jennings A, Mutata C, Ssebunya P, Wamboi C, Green A, Bwakura-Dangarembizi M, Kityo C, Siika A, Archary M, Jafta L, Namukwaya S, Seeley J, Mugerwa H, Walker S, Apoto N, Thomason MJ, Ford D, Pett SL, Kekitiinwa AR; BREATHER Plus trial team. Katongole F, et al. Contemp Clin Trials. 2025 Aug;155:107963. doi: 10.1016/j.cct.2025.107963. Epub 2025 May 29. Contemp Clin Trials. 2025. PMID: 40449658 Free PMC article.
Children living with HIV in Europe: do migrants have worse treatment outcomes?
Chappell E, Kohns Vasconcelos M, Goodall RL, Galli L, Goetghebuer T, Noguera-Julian A, Rodrigues LC, Scherpbier H, Smit C, Bamford A, Crichton S, Navarro ML, Ramos JT, Warszawski J, Spolou V, Chiappini E, Venturini E, Prata F, Kahlert C, Marczynska M, Marques L, Naver L, Thorne C, Gibb DM, Giaquinto C, Judd A, Collins IJ; European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC). Chappell E, et al. HIV Med. 2022 Feb;23(2):186-196. doi: 10.1111/hiv.13177. Epub 2021 Oct 1. HIV Med. 2022. PMID: 34596323 Free PMC article.
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children.
Turkova A, White E, Mujuru HA, Kekitiinwa AR, Kityo CM, Violari A, Lugemwa A, Cressey TR, Musoke P, Variava E, Cotton MF, Archary M, Puthanakit T, Behuhuma O, Kobbe R, Welch SB, Bwakura-Dangarembizi M, Amuge P, Kaudha E, Barlow-Mosha L, Makumbi S, Ramsagar N, Ngampiyaskul C, Musoro G, Atwine L, Liberty A, Musiime V, Bbuye D, Ahimbisibwe GM, Chalermpantmetagul S, Ali S, Sarfati T, Wynne B, Shakeshaft C, Colbers A, Klein N, Bernays S, Saïdi Y, Coelho A, Grossele T, Compagnucci A, Giaquinto C, Rojo P, Ford D, Gibb DM; ODYSSEY Trial Team. Turkova A, et al. N Engl J Med. 2021 Dec 30;385(27):2531-2543. doi: 10.1056/NEJMoa2108793. N Engl J Med. 2021. PMID: 34965338 Free PMC article. Clinical Trial.
Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial.
Turkova A, White E, Kekitiinwa AR, Mumbiro V, Kaudha E, Liberty A, Ahimbisibwe GM, Moloantoa T, Srirompotong U, Mosia NR, Puthanakit T, Kobbe R, Fortuny C, Kataike H, Bbuye D, Na-Rajsima S, Coelho A, Lugemwa A, Bwakura-Dangarembizi MF, Klein N, Mujuru HA, Kityo C, Cotton MF, Ferrand RA, Giaquinto C, Rojo P, Violari A, Gibb DM, Ford D; ODYSSEY trial team. Turkova A, et al. Lancet Child Adolesc Health. 2023 Oct;7(10):718-727. doi: 10.1016/S2352-4642(23)00164-5. Epub 2023 Aug 8. Lancet Child Adolesc Health. 2023. PMID: 37562418 Free PMC article. Clinical Trial.
23 results